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ABSTRACT: 
BACKGROUND: Evidence about the optimal time of day at which to administer statins 
is lacking.  
OBJECTIVE: To synthesize evidence about effects of morning versus evening statin 
administration on lipid profile. 
METHODS: We searched PubMed, SCOPUS, Web of Science and Embase databases 
(from inception up to July 24th, 2016) to identify the relevant studies. Mean 
differences (MDs) between the change scores in lipid parameters were pooled using 
a fixed-effect model. 
RESULTS: Eleven articles with 1034 participants were eligible for the analysis. The 
pooled analysis comparing effects of morning versus evening administration of statins on 
plasma total cholesterol (TC) (p=0.10), high density lipoprotein cholesterol (HDL-C) 
(p=0.90) and triglycerides (TG) (p=0.45) was not statistically significant. Low density 
lipoprotein cholesterol (LDL-C) lowering was statistically greater in the evening-dose 
group (MD: 3.24 mg/dl, 95%CI: 1.23, 5.25, p=0.002). Subgroup analysis according to 
statin half-lives showed that evening-dose of statins was significantly superior to 
morning-dose for lowering LDL-C in case of both short and long half-life statins (MD: 
9.68 mg/dl, 95%CI: 3.32, 16.03, p=0.003, and 2.53 mg/dl, 95%CI: 0.41, 4.64, p=0.02, 
respectively), and also for TC reduction in case of short half-life statins only (p=0.0005). 
CONCLUSIONS: LDL-C and TC lowering were significantly greater in the 
evening-dose than in the morning-dose in case of short-acting statins. Besides slight 
but significant effect on LDL-C, the efficacy of long-acting statins was equivalent for 
both regimens. Therefore, long-acting statins should be given at a time that will best 
aid compliance. Short-acting statins should be given in the evening.   
 
Keywords: Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Half-
Life, Lipids.  
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INTRODUCTION 
Coronary heart disease (CHD) is the leading cause of mortality and morbidity 
worldwide 1,2. It is now unequivocal that elevated levels of total (TC) and low density 
lipoprotein cholesterol (LDL-C) are major risk factors for the development of 
atherosclerosis and CHD, and that lowering these values diminishes the incidence of 
these diseases 3–10. Previous meta-analyses showed that for every 1.0 mmol/L (38.7 
mg/dl) reduction in LDL-C, there is a corresponding 20-25% reduction in cardiovascular 
disease (CVD) mortality 11.  
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 
(statins) are very effective drugs for reducing the elevated levels of plasma cholesterol 
2,12
. Statins reduce both LDL-C and triglycerides (TG) by up to 50% and 20%, 
respectively 2,13. Moreover, they increase high-density lipoprotein cholesterol (HDL-
C) by up to 10% 14,15. It is now well-established that statins are beneficial for primary 
and secondary prevention of CVD 7–10,16–20. In a meta-analysis of 170 000 participants, 
which included data from 26 randomized controlled trials (RCTs) with statins, all-
cause mortality was reduced by 10%, coronary artery disease (CAD) death by 20%, 
risk of major coronary events by 23% and risk of stroke by 17% per 1 mmol/L (38.7 
mg/dL) reduction in LDL-C 21. Statins are considered to be the standard therapy for 
many types of dyslipidemia due their ability to inhibit the endogenous biosynthesis of 
cholesterol and to increase the hepatic uptake of LDL-C by stimulating the expression of 
LDL-C receptors in the liver 11,12,22. This is important because more than 75% of 
cholesterol found in the body is synthesized endogenously and two thirds of it is 
synthesized in the liver alone 12. 
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Statins are usually administrated in the evening because cholesterol biosynthesis 
peaks during the night and also because most of them (simvastatin, pravastatin, 
fluvastatin and lovastatin) have short half-lives 12,23–25. The timing of drug administration 
can alter patient compliance and adherence to the treatment 26–28. Patients treated with 
statins often receive multiple concomitant medications and this leads to more complex 
drug regimens, which have the potential to reduce compliance and adherence to therapy 
29,30
. Allowing flexibility in choosing the time, at which statins are administrated, 
according to the patient`s preference, is likely to improve patient compliance and 
decrease drug discontinuation 31. This will enable more patients to achieve their target 
lipid levels 32,33.  
Therefore, we performed this systematic review and meta-analysis to synthesize 
evidence about the different effects of morning and evening statin administration on lipid 
profiles in order to discover the dosing regimen, which led to the highest therapeutic 
efficacy.    
 
MATERIAL AND METHODS 
We followed preferred reporting items for systematic reviews and meta-analyses 
(PRISMA) statement guidelines during the preparation of this meta-analysis 
(Supplementary File 1: Table S1) 34. This meta-analysis was registered in PROSPERO, 
University of York (CRD42016043480). 
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Search strategy 
 We searched PubMed, SCOPUS, Web of Science and Embase from inception 
until July 24th, 2016 using the following query: (atorvastatin OR fluvastatin OR 
lovastatin OR pitavastatin OR pravastatin OR rosuvastatin OR simvastatin OR 
cerivastatin OR mevinolin OR statin OR statins) AND (morning) AND (evening). 
Additional searches for potential trials included the references of review articles on that 
issue, and the abstracts from selected congresses: scientific sessions of the European 
Society of Cardiology (ESC), the American Heart Association (AHA), American College 
of Cardiology (ACC), European Society of Atherosclerosis (EAS) and National Lipid 
Association (NLA). The wild-card term ‘‘*’’ was used to increase the sensitivity of the 
search strategy. The literature search was limited to articles published in English and to 
studies in humans. 
After removal of duplicates by Endnote X7 (Thompson Reuter, CA, USA), two 
independent authors (K.A. and P.P.) screened the retrieved citations in two steps; the first 
step was to screen the titles and abstracts for eligibility and the second step was to screen 
the full-texts of the eligible abstracts according to the inclusion and exclusion criteria. 
Disagreement was resolved by the opinion of a third author (M.B.) 
 
Study selection  
Original studies were included if they met the following criteria: (ɪ) prospective or 
retrospective clinical controlled studies (with randomized or non-randomized design), (ɪɪ) 
comparing the effects of morning administration against evening administration of statin 
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therapy on one of the following lipid profile parameters: TC, LDL-C, HDL-C or TG, and, 
(ɪɪɪ) reporting sufficient information on blood lipid levels at baseline and at the end of 
study in both groups, or reporting the net change scores or the mean difference between 
the change scores of the two groups. 
 Exclusion criteria were: (ɪ) non-clinical studies, (ɪɪ) studies that contained false 
statements or which had been retracted by the journal, (ɪɪɪ) studies whose full-texts were 
not available, and, (ɪv) studies which provided insufficient data for analysis. 
 
Data extraction 
 Eligible studies were reviewed and the following data were extracted: (1) first 
author’s name, (2) year of publication, (3) study location, (4) study design, (5) 
interventions doses, time and duration; (6) study population characteristics, (7) study 
results, and, (8) concentrations of TC, LDL-C, HDL-C and TG.  
Data extraction was performed independently by 2 reviewers (K.A. and P.P.); 
disagreements were resolved by a third reviewer (M.B.). 
 
Outcomes of interest 
The primary outcome was the mean difference between the change scores of the 
two groups in one of the following lipid parameters: TC, LDL-C, HDL-C and TG. 
Additionally, the secondary outcome was the compliance of patients with statin 
regimens.  
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Quantitative data synthesis 
 Lipid concentrations were collated in mg/dl using the following site to convert 
mmol/L to mg/dl: (http://www.onlineconversion.com/cholesterol.htm). Change scores in 
the lipid levels were calculated as follows: (measure at end of follow-up) – (measure at 
baseline). Standard deviations (SD) of the change scores were calculated using the 
following formula: SD = square root [(SDpre-treatment)2 + (SDpost treatment)2 – (2R × SDpre-
treatment × SDpost-treatment)], assuming a correlation coefficient (R) = 0.5 35–37. If the outcome 
measures were reported as median and range, mean and SD values were estimated using 
the method described by Hozo et al. 38 and if reported as mean and standard error [SE] 
(or confidence interval [CI]), mean and SD values were estimated using the method 
described by Altman et al. 39 Mean difference (MD) between the change scores of the 
morning and evening groups were calculated as follows: (change score of morning group) 
– (change score of evening group) and its SE was calculated using the following formula: 
SE = square root {[(SDtreatment group)2 ÷ ntraetment group] + [(SDcontrol group)2 ÷ ncontrol group]}, 
where (n) was the sample size. If any study reported the MD between the change scores 
of the morning and evening groups directly with 95% CI, SE was calculated using the 
following formula: SE = [(upper confidence limit – lower confidence limit) ÷ 3.92], 
where 3.92 was changed to 3.29 if a 90% CI was given rather than a 95% CI.  
MDs between the change scores of the morning and evening groups were pooled in a 
meta-analysis model with a 95% CI. We used RevMan version 5.3 (The Cochrane 
Collaboration, Oxford, UK) to conduct this analysis.  
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Subgroup analysis  
Data were divided into two subgroups according to the design of the studies as 
follows: (ɪ) RCTs, and (ɪɪ) non-randomized studies. To investigate the impact of statin 
half-lives on the results, data were separately divided into subgroups as follows: (ɪ) short 
half-lives below 7 hours (lovastatin, simvastatin, pravastatin and fluvastatin), and (ɪɪ) 
long half-lives above 7 hours (atorvastatin, rosuvastatin, controlled-release simvastatin 
and extended-release fluvastatin) 12,40–42.  
 
Assessment of heterogeneity 
 Heterogeneity was assessed by visual inspection of the forest plots and was 
measured by I-squared and Chi-squared tests. We interpreted heterogeneity according to 
the recommendations of the Cochrane Handbook of Systematic Reviews and Meta-
analysis in which an alpha level (for Chi-squared test) below 0.1 is considered to be a 
significant heterogeneity, and I-squared test is interpreted as follows: (0–40%: might not 
be important; 30–60%: may represent moderate heterogeneity; 50–90%: may represent 
substantial heterogeneity). In the case of significant heterogeneity, the random effect 
model was used. Otherwise, the fixed effect model was employed in meta-analysis.  
 
Sensitivity analysis 
Sensitivity analysis was conducted using leave-one-out method, i.e. removing one 
study each time and repeating the analysis to determine whether exclusion of any one of 
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the included studies altered the results, particularly when substantial heterogeneity was 
noted between trials. 
 
Quality assessment 
We used the Cochrane Collaboration tool for assessing the risk of bias in included 
RCTs. This tool includes the following domains: sequence generation (selection bias), 
allocation sequence concealment (selection bias), blinding of participants and personnel 
(performance bias), blinding of outcome assessment (detection bias), incomplete outcome 
data (attrition bias), selective outcome reporting (reporting bias) and other potential 
sources of bias. The authors’ judgment is classified as ‘Low risk’, ‘High risk’ or ‘Unclear 
risk’ of bias. 
We used the Newcastle-Ottawa Scale for assessing the risk of bias in non-
randomized studies 43. This scale uses a star system to judge three general domains: 
selection of study groups, comparability of groups and exposure.  
Risk-of-bias assessment was performed independently by 2 reviewers (K.A. and 
P.P.); disagreements were resolved by a third reviewer (M.B.). 
 
Publication bias 
For assessment of publication bias, the pooled effect estimate was plotted against its 
SE in a funnel plot generated by RevMan software and potential publication bias was 
explored by visual inspection of Begg's funnel plot asymmetry, and also we used Egger's 
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weighted regression test to confirm it statistically 44. We used Comprehensive Meta-
Analysis (CMA) V2 software (Biostat, NJ) to perform Egger`s test.   
 
RESULTS 
Flow and characteristics of included studies 
Our search discovered 549 articles. Following removal of duplicates and 
detailed screening, only 11 articles (12 treatment arms)45–55 met our inclusion 
criteria and were eligible for the meta-analysis (see PRISMA flow diagram; Figure 1).  
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Figure 1: Shows the PRISMA flow diagram of studies' screening and selection. 
   
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
In total, 1034 participants were included in our analysis. The number of participants 
in these studies ranged from 12 to 229. Studies included in the meta-analysis were 
published between 1986 and 2014, and were conducted in USA (n = 4), Germany (n = 2), 
Korea (n = 2), Turkey, Japan, UK. The following statin doses were administrated in the 
included studies: 40 mg/day atorvastatin, 2.5-20 mg/day simvastatin, 10 mg/day 
rosuvastatin, 20 mg/day lovastatin, 40 mg/day pravastatin and 80 mg/day fluvastatin. The 
duration of the included studies ranged between 4 weeks and 12 weeks. Nine of the 
included studies were RCTs and one was non-RCT and the other one was a retrospective 
cohort study. The summary of the included studies and their main results are shown in 
Table 1, and the baseline characteristics of their populations are shown in Table 2. 
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Table 1: Summary of the included studies. 
Study Year Location Design Duration Statin used Population Result 
Hurminghake et al 1990 USA Randomized, 
double-blind, 
placebo-
controlled, 
parallel 
trial 
8 weeks pravastatin (40 mg) Patients with primary 
hypercholesterolemia who were 
between the ages of 20 and 72 years. 
Pravastatin was well tolerated and was 
associated with a low incidence of 
adverse events. 
Illingworth et al 1986 USA Non-
randomized, 
controlled, 
trial 
9 weeks mevinolin Patients with severe type II 
hypercholesterolemia (persistent 
primary hypercholesterolemia 
greater than 350 mg/dl) 
Once-daily administration of 
mevinolin, particularly in the evening, 
is an effective hypocholesterolemic 
regimen in patients with familial 
hypercholesterolemia. 
Kim et al 2013 Korea Randomized, 
double-blind, 
controlled, 
parallel 
trial 
8 weeks controlled-release 
simvastatin (20 mg) 
Patients with LDL-C 
levels between 100 and 220 mg/dL 
and triglyceride levels o400 mg/dL 
Although controlled-release 
simvastatin significantly reduces LDL-
C levels with good tolerability in 
Korean adults with dyslipidemia, the 
time of administration does not affect 
its efficacy 
Kruse et al 1993 Germany Randomized, 
single-blind, 
controlled, 
parallel 
trial 
4 weeks lovastatin (20 mg) Patients with familial 
hypercholesterolemia 
The present study adds further 
evidence that drug use seems to be 
more regular in the morning than in the 
evening. 
Martin et al 2002 USA Randomized, 
open-label, 
controlled, 
crossover 
trial 
8 weeks rosuvastatin (10 
mg) 
Healthy adult volunteers, ranging in 
age from 19 to 61 years and 
weighing 57–100 kg 
The therapeutic benefit of rosuvastatin 
is not dose-time dependent, and that 
morning or evening administration is 
equally effective in regulating lipid 
levels 
Ozaydin et al 2006 Turkey Randomized, 
controlled, 
parallel trial 
6 months atorvastatin (40 
mg) 
Patients  with single-vessel coronary 
disease who underwent first elective 
percutaneous coronary 
intervention (PCI) 
Compared with the intake of 
atorvastatin in the morning, intake in 
the evening before PCI was associated 
with a more pronounced decrease in 
total cholesterol, LDL cholesterol, and 
triglyceride values, and an increase in 
HDL cholesterol levels 
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Plakogiannis et al 2005 USA Retrospective 
cohort 
4 weeks atorvastatin (40 
mg) 
Hyperlipidemic patients at the New 
York Harbor Healthcare System 
(NYHHS) 
Changes in the levels of total 
cholesterol, LDL cholesterol, 
triglycerides, and HDL cholesterol 
were similar among hyperlipidemic 
patients receiving atorvastatin calcium 
40 mg daily, regardless of the time of 
day the drug was administered 
Saito et al 1991 Japan Double-
blind, 
placebo-
controlled, 
parallel 
trial 
12 weeks Simvastatin (2.5 or 
5 mg) 
Patients diagnosed as having 
hyperlipidemia (a serum cholesterol 
value of at least 220 mg/dl , 
including patients with familial 
hypercholesterolemia) 
When simvastatin was administered 
orally once per day in the evening, it 
reduced cholesterol levels to a 
significantly greater degree than when 
it was given in the morning 
Scharnagl et al 2006 Germany Randomized, 
double-blind, 
controlled, 
parallel 
trial 
8 weeks Fluvastatin 
Extended 
Release (80 mg) 
Patients aged 35–80 years and have 
type IIa/b hypercholesterolemia 
(Frederickson), and LDL-C 
≥ 160 mg/dl and triglycerides (TG) < 
400 mg/dl in the absence of lipid-
lowering treatment 
The efficacy and safety profiles of 
fluvastatin Extended Release are 
equivalent for morning and evening 
administration 
Wallace et al  2003 UK Randomized, 
controlled, 
parallel trial 
8 weeks simvastatin (10 or 
20 mg) 
Adults stable on 10 or 20 mg of 
simvastatin at night for primary or 
secondary prevention of coronary 
heart disease, stroke, or peripheral 
vascular disease 
Simvastatin is probably best taken at 
night because concentrations of total 
cholesterol and of low density 
lipoprotein are significantly greater 
when it is taken in the morning 
Yi et al 2014 Korea Randomized, 
double-blind, 
controlled, 
parallel 
trial 
8 weeks simvastatin (20 mg) Patients, 20 to 75 years of age, with 
CKD stage 3, 4, or 5 (predialysis) 
were enrolled if their serum LDL-C 
levels were between 100 and 220 
mg/dL and their serum triglyceride 
(TG) levels were < 400 mg/dL 
The efficacy of morning administration 
of CR simvastatin was non-inferior to 
evening administration of IR 
simvastatin in patients with CKD. 
Morning administration of CR 
simvastatin is expected to increase 
patient compliance and therefore better 
control of dyslipidemia in CKD 
patients 
Abbreviations: LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; CR: controlled release; IR: immediate release; 
CKD: chronic kidney disease
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Table 2: Baseline characteristics of the included studies.  
Study Year Group (# of 
Patients) 
Age 
(years) 
Weight 
(kg) 
Gender 
(m/f) 
Total 
cholesterol 
(mg/dl) 
LDL-C 
(mg/dl) 
HDL-C 
(mg/dl) 
Triglycerides 
(mg/dl) 
Hurminghak
e et al 
1990 Pravastatin qam 
(n = 48) 
53.3 79.1 36/12 320.2 
(69.7) 
245.6 
(67) 
44.5 (10.7) 127.5 (49) 
Pravastatin qpm 
(n = 43) 
54.0 76.4 30/13 320.6 
(73.5) 
244.8 
(73.5) 
44.5 (12.7) 126.7 (69.7) 
Illingworth et 
al 
1986 Mevinolin qam 
versus  
Mevinolin qpm  
(n = 12) 
54 
(13.9) 
67 
(10.4) 
4/8 440 (48.5) 357 
(48.5) 
54 (17.3) 147 (45) 
54 
(13.9) 
67 
(10.4) 
4/8 440 (48.5) 357 
(48.5) 
54 (17.3) 147 (45) 
Kim et al 2013 Simvastatin qam 
(n = 61) 
58.7 
(8.3) 
66.1 
(11.0) 
26/35 236.0 
(28.9) 
155.0 
(22.3) 
48.6 (9.7) 157.1 (65.2) 
Simvastatin qpm 
(n = 62) 
58.5 
(9.5) 
66.6 
(9.5) 
29/33 238.4 
(31.1) 
160.6 
(25.0) 
50.3 (11.3) 147.3 (63.1) 
Kruse et al 1993 Lovastatin qam 
(n = 12) 
48.4 
(11.4) 
74.7 
(5.2) 
9/3 424.6 
(129.9) 
338.7 
(111.2) 
36.3 (10.7) 178.9 (92) 
Lovastatin qpm 
(n = 12) 
45 
(9.7) 
74.3 
(11.8) 
8/4 450.9 
(87.1) 
379.7 
(80.4) 
40.2 (8) 130.2 (52) 
Martin et al 2002 rosuvastatin 
qam (n = 21) 
NS NS NS 191 120.7 49.5 105.4 
rosuvastatin 
qpm (n = 21) 
NS NS NS 189.5 119.5 47.6 112.5 
Ozaydin et al 2006 Atorvastatin 
qam (n = 73) 
59 (6) NS 59/14 211 (26) 140 (14) 35 (3) 175 (27) 
Atorvastatin 
qpm (n = 79) 
58 (5) NS 59/20 206 (18) 138 (13) 37 (4) 170 (21) 
Plakogiannis 
et al 
2005 Atorvastatin 
qam (n = 32) 
58.5 
(7.8) 
NS 32/0 321.4 
(28.0) 
188.3 
(13.0) 
46.4 (8.9) 434.0 (87.2) 
Atorvastatin 
qpm (n = 32) 
57.8 
(7.8) 
NS 32/0 329.2 
(23.3) 
195.0 
(10.4) 
40.8 (5.5) 468.5 (93.0) 
Saito et al 1991 Simvastatin 2.5 
mg qam (n = 30) 
NS NS 8/22 273.0 
(39.6) 
182.7 
(46.8) 
54.38 
(24.26) 
179.6 (105.3) 
Simvastatin 2.5 
mg qpm (n = 28) 
NS NS 6/22 274.9 
(37.2) 
195.9 
(36.7) 
46.95 
(15.00) 
160.3 (72.3) 
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Simvastatin 5 
mg qam (n = 32) 
NS NS 8/24 277.4 
(49.8) 
194.2 
(48.1) 
52.71 
(17.94) 
152.5 (77.4) 
Simvastatin 5 
mg qpm (n = 29) 
NS NS 4/25 288.8 
(46.9) 
204.3 
(52.2) 
53.15 
(12.97) 
156.3 (68.9) 
Scharnagl et 
al 
2006 Fluvastatin qam 
(n = 109)  
60.1 NS 38/71 282.3 
(32.6) 
189.9 
(27.6) 
58 (16.5) 176 (80.7) 
Fluvastatin qpm 
(n = 120) 
60.6 NS 49/71 282.5 
(35.4) 
188.5 
(32.9) 
59.4 (16.3) 176.4 (74.4) 
Wallace et al 2003 Simvastatin qam 
versus 
simvastatin qpm 
(n = 60) 
66 NS 27/33 170.1 
(30.9) 
92.8 (23) 50 (11.6) 141.7 (70.9) 
Yi et al 2014 CR simvastatin 
qam (n = 59) 
56.9 
(10.5) 
64.3 
(11.1) 
28/31 228.7 
(36.8) 
143.9 
(28.1) 
46.9 (14.5) 190.3 (73.0) 
IR simvastatin 
qpm (n = 59) 
57.0 
(12.1) 
63.7 
(10.4) 
29/30 220.0 
(36.4) 
137.0 
(28.4) 
48.8 (13.5) 167.6 (70.7) 
Continuous variables are described as Mean or Mean (SD) and categorical variables are described as N. 
Abbreviations: NS: not stated; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein 
cholesterol; m: male; f: female; qam: every morning; qpm: every evening; CR: controlled release; IR: 
immediate release  
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Quality of the included studies 
According to Cochrane Collaboration tool and Newcastle-Ottawa Scale, the quality 
of the included studies ranged from low to high quality. The summary of quality 
assessment domains of included studies is shown in Tables 3 & 4.   
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Table 3: Assessment of risk of bias in the included randomized controlled trials using Cochrane criteria. 
 
Study Sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
outcome 
reporting 
Other 
potential 
threats to 
validity 
Hurminghake (1990) U U L U L U L 
Kim (2013) L L L U L U L 
Kruse (1993) U U L H L U L 
Martin (2002) U U H H L U L 
Ozaydin (2006) U U H L L U H* 
Saito (1991) U U L U L U L 
Scharnagl (2006) U U L U L U L 
Wallace (2003) U U H H L U L 
Yi (2014) U U L U L U H** 
 
L: low risk of bias; H: high risk of bias; U: unclear risk of bias. 
 
*Differences in baseline characteristics 
** Different formulation used: controlled release in the morning and immediate release in the evening groups. 
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Table 4: Assessment of the Quality of non-randomized studies using the Newcastle-Ottawa Scale 
Domain and Topic (max. 10 stars) 
Author Year 
Selection 
(max. 5 stars) 
Comparability 
(max. 2 stars) 
Outcome 
(max. 3 stars) 
Total 
Representativene
ss 
of the sample 
Selection of 
the non 
exposed 
cohort # 
Ascertainmen
t 
of the 
exposure 
Demonstration 
that outcome of 
interest was not 
present at start of 
study ## 
Subjects in 
different 
outcome 
groups are 
comparable 
Assessment 
of Outcome 
Was 
follow-up 
long 
enough for 
outcomes 
to occur 
Adequa
cy of 
follow 
up of 
cohorts 
Illingworth 1986 * * * * * * * * 8 
Plakogiannis 2005 * * * * * * * * 8 
 
#    Comparability of selection of baseline day and night groups  
##  Reporting of baseline plasma lipid values 
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Efficacy analysis 
The overall pooled analysis of 11 studies (12 treatment arms) comparing effects of 
morning versus evening administration of statins on plasma TC (MD: 1.68 mg/dl, 
95%CI: -0.33, 3.69, p=0.10, Figure 2), HDL-C (MD: 0.05 mg/dl, 95%CI: -0.77, 0.87, 
p=0.90, Figure 3) and TG (MD: 1.66 mg/dl, 95%CI: -2.68, 5.99, p=0.45, Figure 4) was 
not statistically significant. However, it favored evening-dose over morning-dose with 
respect to the effect of statins on plasma LDL-C (MD: 3.24 mg/dl, 95%CI: 1.23, 5.25, 
p=0.002, Figure 5). No significant heterogeneity was noted for any of the outcomes (Chi 
square p>0.1) 
The pooled analysis of the short half-life statins subgroup did not reveal any 
significant difference between the morning-dose and evening-dose groups in terms of 
HDL-C (MD: 0.28 mg/dl, 95%CI: -1.49, 2.06, p=0.75, Figure 3) and TG (MD: 0.97 
mg/dl, 95%CI: -13.54, 15.48, p=0.90, Figure 4). However, it favored evening-dose over 
morning-dose in terms of TC (MD: 12.10 mg/dl, 95%CI: 5.25, 18.95, p=0.0005, Figure 
2) and LDL-C (MD: 9.68 mg/dl, 95%CI: 3.32, 16.03, p=0.003, Figure 5). For all 
outcomes there was no significant heterogeneity (Chi square p>0.1).  
The pooled analysis of the long half-life statins subgroup did not show any 
significant difference for TC (MD: 0.70 mg/dl, 95%CI: -1.40, 2.80, p=0.51, Figure 2), 
HDL-C (MD: -0.01 mg/dl, 95%CI: -0.94, 0.92, p=0.98, Figure 3) and TG (MD: 1.72 
mg/dl, 95%CI: -2.82, 6.27, p=0.46, Figure 4). However, it favored evening-dose over 
morning-dose in term of LDL-C (MD: 2.53 mg/dl, 95%CI: 0.41, 4.64, p=0.02, Figure 5). 
No significant heterogeneity was noted for any of the outcomes (Chi square p>0.1).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
 
Figure 2: Forest plot displaying the results of the meta-analysis of morning vs evening statins on 
total cholesterol with subgrouping according to half-lives of statins. CI, confidence interval; df, 
degrees of freedom; SE, standard error. 
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Figure 3: Forest plot displaying the results of the meta-analysis of morning vs evening statins on 
high density lipoprotein cholesterol with subgrouping according to half-lives of statins. CI, 
confidence interval; df, degrees of freedom; SE, standard error. 
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Figure 4: Forest plot displaying the results of the meta-analysis of morning vs evening statins on 
triglycerides with subgrouping according to half-lives of statins. CI, confidence interval; df, 
degrees of freedom; SE, standard error. 
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Figure 5: Forest plot displaying the results of the meta-analysis of morning vs evening statins on 
low density lipoprotein cholesterol with subgrouping according to half-lives of statins. CI, 
confidence interval; df, degrees of freedom; SE, standard error. 
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The pooled analysis of RCTs subgroup did not reveal any significant difference 
between the two groups concerning their effects on plasma TC (MD: 1.59 mg/dl, 95%CI: 
-0.45, 3.63, p=0.13, Supplementary File 2: Figure S1), HDL-C (MD: 0.03 mg/dl, 
95%CI: -0.82, 0.87, p=0.95, Supplementary File 2: Figure S2) and TG (MD: 1.65 
mg/dl, 95%CI: -2.73, 6.03, p=0.46, Supplementary File 2: Figure S3). However, it 
favored evening-dose over morning-dose with respect to the effect of statins on plasma 
LDL-C (MD: 3.49 mg/dl, 95%CI: 1.31, 5.68, p=0.002, Supplementary File 2: Figure 
S4). No significant heterogeneity was noted for any outcomes (Chi square p>0.1). The 
combined analysis of non-randomized studies did not reveal any significant difference 
between the morning-dose and evening-dose groups on any of the investigated outcomes: 
plasma TC (MD: 4.22 mg/dl, 95%CI: -6.62, 15.06, p=0.45, Supplementary File 2: 
Figure S1), HDL-C (MD: 0.55 mg/dl, 95%CI: -3.2, 4.3, p=0.77, Supplementary File 2: 
Figure S2), TG (MD: 2.06 mg/dl, 95%CI: -27.85, 31.97, p=0.89, Supplementary File 2: 
Figure S3) and LDL-C (MD: 1.86 mg/dl, 95%CI: -3.27, 6.98, p=0.48, Supplementary 
File 2: Figure S4). No significant heterogeneity was noted for any outcomes (Chi square 
p>0.1).  
 
Compliance with both regimens 
Only three studies 46,47,52 of the 11 included in this meta-analysis reported the 
rates of compliance with both statin regimens. Two of them 46,52 revealed no 
significant difference between the two regimens, and one study 47 indicated that 
drug compliance was better when the drug was taken in the morning than in the 
evening. Compared with morning-dosing, evening-dosing of lovastatin was 
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associated with a 7% reduction in the number of prescribed doses, which were 
taken by the patient. 47.    
 
Sensitivity analysis 
For all efficacy outcomes, the overall pooled effect size was robust and the statistical 
significance or non-significance of the differences between groups was not altered in the 
leave-one-out sensitivity analysis. This means that none of the included studies 
individually changed the overall result. However, the pooled analyses of effects of 
morning-dose versus evening-dose of short half-life statins on LDL-C and TC were 
sensitive to the study by Wallace et al. 52, because of the substantial weight of this study, 
i.e. removing this study from the analysis led to no significant difference being detectable 
between the groups. In long half-life statins, the pooled effect on LDL-C was sensitive to 
the studies by Martin et al. 48 and Ozaydin et al. 49 because of the substantial weights of 
these studies. Summary of the leave-one-out sensitivity analysis is shown in 
(Supplementary File 3: Table S2).    
 
Publication bias  
Visual inspection of the funnel plots suggested a potential publication bias for 
the effects of morning-dose versus evening-dose of statin on plasma TC and LDL-C 
(Supplementary File 2: Figures S5 & S6). However, the funnel plots were symmetric 
in the case of the effects of statins on TG and HDL-C (Supplementary File 2: 
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Figures S7 & S8). In contrast, the Egger`s test statistically excluded the presence of 
publication bias for all outcomes (two-tailed p>0.05).  
 
DISCUSSION 
To our knowledge, this meta-analysis is the first to compare the effects of morning 
and evening doses of statin therapy on lipid profiles. Data from 11 studies showed that 
the LDL-C–lowering effect of the drugs was significantly greater when statins were taken 
in the evening than when they were taken in the morning. This effect was independent of 
the half-live of the drugs used. In the case of short half-life statins, evening-dosing 
resulted in a larger TC-lowering effect. The evening-dosing and morning-dosing 
regimens were equivalent with respect to the effects of statins on HDL-C and TG.  
The US Food and Drug Administration (FDA) recommends evening 
administration of lovastatin,56 simvastatin,57and fluvastatin58. This is based on their 
short half-lives (2-3, 2-3 and 0.5-2.3 hours respectively) and the fact that peak 
cholesterol biosynthesis occurs during the night 12,25,40,59. It is advised that 
atorvastatin,60 rosuvastatin,61and extended-release fluvastatin42,58 can be given at 
any time of  day due to their long half-lives (15-30, 30 and 7.3-10.5 hours 
respectively). The results of this meta-analysis are in line with these 
recommendations. However, the FDA advises that pravastatin can be taken at any 
time of the day despite its short half-life (1.3-2.8 hours) 12,40,62. This might be because 
the systemic bioavailability of pravastatin is decreased by 60% when administrated 
in the evening compared with that following the morning dose 63. However, the 
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evening dose of pravastatin was found to be marginally more effective than the 
morning dose. Our finding that LDL-C lowering was greater when statins with long half-
lives were administered in the evening, than when they were taken in the morning is 
somewhat unexpected. However, it should be noted that the difference between the 
groups is small and might be not clinically relevant. However, under the assumption that 
a 1 mmol/l (38.7 mg/dl) reduction in LDL-C is associated with a 20-25% reduction in 
CVD mortality,11 this difference might have been associated with a 0.3-3% reduction in 
CVD mortality at the population-level.  
 Adherence to statin treatment remains problematic, and affects the clinical 
effectiveness of these drugs 64,65. There are many factors that affect statin adherence such 
as adverse effects (statin associated muscle symptoms / statin intolerance), complex drug 
regimens, drug-drug interactions, patient preference (rather than provider preference), 
cost, age and gender 66–70. Good adherence to statin has been associated with a 15-20% 
lower risk of CVD events 71. Some other studies have reported a much greater reduction 
that may reach up to 40% 72–77. Regimens requiring evening doses of cardiovascular 
drugs have been associated with a 5-25% drop in compliance when compared with 
administration in the morning 78–80. One of the studies included in this meta-analysis 
reported a 7% reduction in the number of the prescribed doses of lovastatin, which 
were taken when the drug was directed to be taken in the evening, compared with  
morning doses 47. One important factor that may help to improve adherence is to allow 
patients to decide at which time of the day they prefer to take their statin (e.g. with other 
medication in the morning) 31,80. This selected time should be the one most likely to result 
in an uninterrupted intake of the medicine 31. However, some prescribers may insist on 
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patients taking statins in the evening because they are under the impression that these 
drugs are substantially more effective when taken at night. Based on the results of this 
meta-analysis, evening dosing appears to be important for short-acting statins, but in the 
case of statins with long half-lives, prescribing instructions should allow more patient-
based choice. In addition, it should be emphasized that taking the statin at the same time 
every day (e.g. developing a morning routine) might result in better adherence 31,80.  
Patients treated with statins often receive multiple concomitant drugs 30. 
Polypharmacy and complex drug regimens have been associated with decreased 
adherence 29. Taking multiple medications at the same time or in the form of a 
‘polypill’ has been proposed a possible solution to the complexity of drug regimens, 
and has been associated with increased adherence81,82. However, many of the drugs, 
which might be administered concomitantly with statins are usually administrated 
in the morning (e.g. antihypertensive drugs and aspirin) 83. The results of our 
analysis are important because they clearly confirm that administration of long-
acting statins in the morning is as efficacious as administration in the evening. 
Therefore, the efficacy of long-acting statins will not be altered when administrated, 
in a polypill, with these concomitant medications in the morning.         
This meta-analysis has several limitations: most importantly, the sample size of each 
individual study was relatively small (12 to 229 participants), and the follow-up was 
relatively short (4-12 weeks). Secondly, some of the included studies did not have a well-
defined exclusion criteria 48,52,54. Thirdly, the difference in effects of morning-dose versus 
evening-dose of statins was a secondary finding in some of included studies 45,47,49,54. 
Fourthly, the patient population in the included studies was heterogeneous with respect to 
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various factors including health, hyperlipidemia and chronic kidney disease (CKD). 
Fifthly, most of the included studies did not report the results of patients’ 
compliance with statin regimens. 
Bearing in mind the limitations of the current evidence, further well-designed, 
large-scale RCTs are required to confirm our results and to investigate long-term 
compliance with morning and evening regimens of statins. In 2011, Wright et al. 
investigated the effect of the timing of simvastatin on its efficacy in a 
pharmacokinetic–pharmacodynamics model 80. They found no clinically important 
difference between morning and evening doses. They explained this result by the 
relativity slow turnover of the cholesterol in the plasma (3-4 days) and, in turn, the 
delayed peak effect of simvastatin on LDL-C reduction 84,85. Therefore, the 
chronobiologic effects of short-acting statins should be further established in large-
scale RCTs.        
In conclusion, the current meta-analysis shows that LDL-C and TC lowering were 
significantly greater in the evening-dose than in the morning-dose in case of short-acting 
statins. However, apart from a small but statistically significant effect on LDL-C, the 
efficacy of long-acting statins was equivalent for morning and evening administration. 
Therefore, it would be appropriate to consider choosing the time of administration of 
long-acting statins based upon what will best aid compliance. On the other hand, short-
acting statins should be taken in evening. Future well-designed, large-scale, prospective 
RCTs are recommended, especially on short-acting statins, to confirm our findings.  
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• LDL-C lowering was greater in the evening-dose of short and long half-life 
statins. 
• TC lowering was greater in the evening-dose of short half-life statins only.  
• Morning-dose was equivalent to evening-dose in terms of HDL-C and TG. 
 
